Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.71 Insider Own0.21% Shs Outstand46.74M Perf Week3.14%
Market Cap1.12B Forward P/E- EPS next Y-2.27 Insider Trans0.00% Shs Float46.66M Perf Month14.63%
Income-77.00M PEG- EPS next Q-0.51 Inst Own- Short Float9.94% Perf Quarter-22.06%
Sales4.10M P/S273.81 EPS this Y18.40% Inst Trans8.18% Short Ratio6.72 Perf Half Y-31.03%
Book/sh8.52 P/B3.16 EPS next Y-12.80% ROA-20.10% Target Price64.83 Perf Year-19.38%
Cash/sh9.14 P/C2.95 EPS next 5Y- ROE-21.40% 52W Range19.85 - 57.20 Perf YTD-30.23%
Dividend- P/FCF- EPS past 5Y38.70% ROI-16.90% 52W High-59.63% Beta2.49
Dividend %- Quick Ratio26.80 Sales past 5Y-7.30% Gross Margin- 52W Low16.32% ATR2.14
Employees132 Current Ratio26.80 Sales Q/Q-71.40% Oper. Margin- RSI (14)41.22 Volatility9.17% 8.10%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.10% Profit Margin- Rel Volume6.11 Prev Close26.96
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume689.70K Price23.09
Recom1.50 SMA20-5.81% SMA50-16.19% SMA200-36.00% Volume3,567,289 Change-14.35%
Sep-17-21Initiated Jefferies Buy $66
Sep-10-21Initiated SVB Leerink Outperform $68
Jul-22-21Initiated Guggenheim Buy $66
Feb-21-20Initiated Cantor Fitzgerald Overweight $8
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jul-01-22 10:11AM  
Jun-30-22 06:01PM  
Jun-22-22 09:24AM  
Jun-21-22 08:00AM  
Jun-20-22 10:35AM  
Jun-16-22 04:01PM  
Jun-06-22 04:05PM  
May-19-22 09:23AM  
May-11-22 08:13AM  
May-06-22 08:10AM  
May-05-22 05:55PM  
May-04-22 08:25AM  
Feb-28-22 04:01PM  
Feb-22-22 04:01PM  
Feb-17-22 03:07AM  
Feb-13-22 07:47AM  
Feb-10-22 04:05PM  
Feb-02-22 01:38PM  
Jan-10-22 08:40AM  
Dec-15-21 04:57AM  
Dec-11-21 06:53PM  
Dec-08-21 08:01AM  
Nov-12-21 07:00AM  
Nov-11-21 07:01AM  
Nov-09-21 06:15PM  
Oct-28-21 03:05PM  
Oct-25-21 11:51AM  
Sep-29-21 08:13AM  
Sep-24-21 07:01AM  
Sep-23-21 08:01AM  
Sep-16-21 07:01AM  
Sep-14-21 10:31AM  
Sep-13-21 09:01AM  
Aug-25-21 03:55PM  
Aug-05-21 06:05PM  
Jul-29-21 03:05PM  
Jul-24-21 07:04AM  
Jul-18-21 03:39AM  
Jul-16-21 04:01PM  
Jul-14-21 03:21PM  
Jul-13-21 08:30PM  
Jul-12-21 04:27PM  
Jul-09-21 06:01PM  
Jun-04-21 09:01AM  
Jun-01-21 07:31AM  
May-26-21 04:01PM  
May-13-21 03:18AM  
May-06-21 06:35PM  
Apr-20-21 11:56AM  
Apr-12-21 04:01PM  
Apr-10-21 06:13AM  
Apr-06-21 09:05AM  
Mar-29-21 04:01PM  
Mar-05-21 01:00PM  
Feb-23-21 06:01AM  
Feb-22-21 04:01PM  
Jan-26-21 12:39AM  
Jan-08-21 08:51AM  
Jan-04-21 08:01AM  
Dec-23-20 06:55AM  
Dec-09-20 08:01AM  
Nov-30-20 04:01PM  
Nov-27-20 12:30AM  
Nov-09-20 08:01AM  
Nov-05-20 05:55PM  
Nov-03-20 12:31PM  
Oct-15-20 08:14PM  
Oct-14-20 11:32AM  
Oct-13-20 08:01AM  
Oct-06-20 06:09PM  
Sep-29-20 08:58AM  
Sep-10-20 04:01PM  
Aug-25-20 01:25PM  
Aug-24-20 08:01AM  
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martin Samuel BatesSVP and CFODec 23Option Exercise5.687,00039,72933,878Dec 28 04:02 PM
Martin Samuel BatesSVP and CFODec 23Sale42.009,500399,00024,378Dec 28 04:02 PM
Crowley ElizabethSr. VP &CPDODec 08Option Exercise9.024,00036,0668,726Dec 10 04:02 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsDec 08Option Exercise2.786001,66811,847Dec 10 04:02 PM
Cavanaugh SarahSVP of Corp Affairs & Admin.Dec 08Option Exercise10.037,32373,4817,731Dec 10 04:03 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsDec 08Sale40.0060024,00011,247Dec 10 04:02 PM
Crowley ElizabethSr. VP &CPDODec 08Sale40.004,000160,0004,726Dec 10 04:02 PM
Cavanaugh SarahSVP of Corp Affairs & Admin.Dec 08Sale40.007,323292,920408Dec 10 04:03 PM
Martin Samuel BatesSVP and CFONov 15Option Exercise5.687,00039,72936,378Nov 17 04:02 PM
Martin Samuel BatesSVP and CFONov 15Sale43.579,500413,88326,878Nov 17 04:02 PM
Young Diane C.SVP, Chief Medical OfficerNov 12Option Exercise10.384,60047,7486,715Nov 16 04:02 PM
Young Diane C.SVP, Chief Medical OfficerNov 12Sale42.944,600197,5292,115Nov 16 04:02 PM
Crowley ElizabethSr. VP &CPDONov 01Option Exercise2.788,55523,7839,043Nov 03 04:02 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsNov 01Option Exercise2.786001,66811,847Nov 03 04:02 PM
Cavanaugh SarahSVP of Corp Affairs & Admin.Nov 01Option Exercise8.035,95647,8527,731Nov 03 04:02 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsNov 01Sale41.7160025,02611,247Nov 03 04:02 PM
Crowley ElizabethSr. VP &CPDONov 01Sale43.294,317186,8744,726Nov 03 04:02 PM
Cavanaugh SarahSVP of Corp Affairs & Admin.Nov 01Sale43.267,323316,804408Nov 03 04:02 PM
Heath-Chiozzi MargoSVP of Regulatory AffairsAug 11Option Exercise9.0210,00090,16511,247Aug 13 06:59 AM
Jimenez Freddy A.SVP & General CounselAug 11Buy46.2843019,900430Aug 13 06:58 AM
Martin Samuel BatesSVP and CFOAug 10Option Exercise5.7821,381123,68830,060Aug 12 10:00 AM
Martin Samuel BatesSVP and CFOAug 10Sale45.252,738123,89418,981Aug 12 10:00 AM
Marucci Anthony SPresident & CEOAug 05Option Exercise42.003,537148,55427,231Aug 09 07:21 AM